References
- Parfitt AIVI, Mathews C, Rao D, et al. Impaired osteoblast function in metabolic disease. In DeLuca HF, Frost HM, Jee WSS, et al., eds. Osteoporosis: Recent Advances in Pathogenesis and Treatment. Baltimore, MD: University Park Press, 1981:321–30
- Christiansen C, Riis B, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105–8
- Dodin S, Lemay A, Maheux R, et al. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991;77:410–15
- Compston JE, Yamaguchi K, Croucher PI, et al. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16: 261–7
- Amama EA, Taga M, Minaguchi H. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover. J Gun Endocrinol Metab 1998;83:333–8
- Ohta H, Masuda A, Komukai S, et al. Osteoporosis after menopause and oophorectomy. Nippon Rinsho 1994;52:2382–94
- Nencioni T, Penotti M, Barbieri-Carones M, et al. Gonadotropin releasing hormone agonist therapy and its effect on bone mass. Gynecol Endocrinol 1991;5:49–56
- Wendlova J. Ntx - a sensitive laboratory parameter of bone resorption. Bratisl Lek Listy 1998;99:327–30
- Riis BJ. Biochemical markers of bone turnover. II: Diagnosis, prophylaxis and treatment of osteoporo-sis. Am J Med 1993;95:17S–21S
- Nakayama H, Yano T, Sagara Y, et al. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism. Endocr J 1997;44:479–84
- Mann DR, Gould KG, Collins DC. A potential primate model for bone loss resulting from medical oophorectomy or menopause. J Gun Endocrinol Metab 1990;71:105–10
- Sims NA, Morris HA, Moore RJ, et al. Increased bone resorption precedes increased bone formation in the ovariectomized rat. Galt-if Tissue Int 1996;59:121–7
- Tummon IS, Ali A, Pepping ME, et al. Bone mineral density in women with endometriosis before and during ovarian suppression with gona-dotropin releasing hormone agonists or danazol. Fertil Steril 1988;49:792–6
- Stevenson JC, Lees B, Gardner R, et al. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endome-triosis. Horm Res 1989;32\(Suppl. 1):161–4
- Dawood MY. Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 1993;168: 674–84
- Uemura T, Mohri J, Osada H, et al. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril 1994;62:246–50
- Taga M, Minaguchi H. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 1996;75:162–5
- Zhang M, He Y, Cao S. Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism. Zhonghua Fu Chan Ke Za Zhi 1995;30:398–401
- Adamson GD, Heinrichs WL, Henzl MR, et al. Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel). Am J Obstet Gynecol 1997;177:1413–18
- Dmowski WP, Rana N, Pepping P, et al. Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss. Fertil Steril 1996;66:929–36
- Ulrich U, Pfeifer T, Lauritzen C. Rapid increase in lumbar spine bone density in osteoporotic women by high dose intramuscular estrogen—progestogen injections. A preliminary report. Horm Metab Res 1994;26:428–31.